{"id":55891,"date":"2023-04-17T16:03:07","date_gmt":"2023-04-17T14:03:07","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/halda-therapeutics-presents-preclinical-data-for-riptac-therapeutics-demonstrating-oral-efficacy-as-a-monotherapy-for-the-treatment-of-prostate-cancer\/"},"modified":"2023-04-17T16:03:07","modified_gmt":"2023-04-17T14:03:07","slug":"halda-therapeutics-presents-preclinical-data-for-riptac-therapeutics-demonstrating-oral-efficacy-as-a-monotherapy-for-the-treatment-of-prostate-cancer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/halda-therapeutics-presents-preclinical-data-for-riptac-therapeutics-demonstrating-oral-efficacy-as-a-monotherapy-for-the-treatment-of-prostate-cancer\/","title":{"rendered":"Halda Therapeutics Presents Preclinical Data for RIPTAC\u2122 Therapeutics Demonstrating Oral Efficacy as a Monotherapy for the Treatment of Prostate Cancer"},"content":{"rendered":"
\n

\nPresentation at AACR highlights the \u201chold and kill\u201d mechanism of RIPTAC therapeutics in prostate cancer models including clinically relevant androgen receptor mutants<\/i><\/p>\n

\nHalda has a pipeline of orally-available RIPTAC therapeutics<\/i> which are heterobifunctional small molecules designed to treat cancer selectively and overcome common drug resistance<\/i><\/p>\n

NEW HAVEN, Conn.–(BUSINESS WIRE)–Halda Therapeutics<\/a>, a biotechnology company developing a novel class of cancer therapies called RIPTACTM<\/sup> (Regulated Induced Proximity TArgeting Chimeras) therapeutics, today announced a poster presentation for its lead RIPTAC therapeutic program for prostate cancer at the annual meeting of the American Association for Cancer Research (AACR) being held in Orlando, Florida, from April 14-19, 2023. The preclinical data showed oral efficacy of the RIPTAC therapeutics as a monotherapy and demonstrated anti-tumor activity superior to the standard of care agent in prostate cancer, enzalutamide. Combination therapy with PARP inhibitors is also being explored and RIPTAC therapeutics may have a complementary mechanism.<\/p>\n

<\/a><\/p>\n

\n\u201cOur presentation at AACR is an exciting opportunity to share the growing body of evidence demonstrating the anti-tumor efficacy of the \u201chold and kill\u201d mechanism of RIPTAC therapeutics which can be applied to address cancers in early or later-line therapy,\u201d said Kat Kayser-Bricker, PhD, Chief Scientific Officer of Halda Therapeutics. \u201cThese preclinical efficacy results of RIPTAC therapeutics targeting prostate cancer highlight the promise of a novel approach to overcome bypass mechanisms of resistance that evolve during cancer therapy, which is a common limitation of today\u2019s precision oncology medicines.\u201d<\/p>\n

\nThe preclinical data describe the anti-tumor activity of prostate cancer RIPTAC therapeutics, novel orally bioavailable heterobifunctional small molecules, that use a unique \u201chold and kill\u201d mechanism resulting in selective cancer cell killing by bringing together two proteins: the tumor-specific protein androgen receptor (AR) and an essential protein involved in transcription regulation. A trimeric complex is formed by the prostate cancer RIPTAC therapeutic and the two proteins which drives the formation of new protein-protein interactions; the resultant trimeric species thereby abrogates the function of the essential protein within AR-expressing prostate cancer cells, leading to selective cancer cell death.<\/p>\n

\nThe poster presentation, with lead author Xinheng Yu, PhD, Research Investigator at Halda, is entitled \u201cProstate Cancer RIPTACTM <\/sup>Therapeutics Demonstrate Activity in Preclinical Models of Enzalutamide-Resistant Prostate Cancer,\u201d and includes the following results:<\/p>\n